NovoCure Limited

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-13 pm EDT			5-day change	1st Jan Change
10.72 ^USD	+1.32%		+1.61%	-17.09%

Apr. 01	Zymeworks Inc. Announces Executive Changes, Effective from April 1, 2026	CI
Apr. 01	Zymeworks Inc. Announces Chief Financial Officer Changes, Effective April 1, 2026	CI

Published on 02/26/2026 at 11:05 am EST - Modified on 03/16/2026 at 12:08 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, and thank you for standing by. Welcome to the NovoCure Fourth Quarter 2025 Earnings Call. [Operator Instructions] Please be advised that

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Apr. 01	Zymeworks Inc. Announces Executive Changes, Effective from April 1, 2026	CI
Apr. 01	Zymeworks Inc. Announces Chief Financial Officer Changes, Effective April 1, 2026	CI
Mar. 26	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Ongoing Middle East Tensions	MT
Mar. 26	NovoCure Says Phase 2 Trial of TTFields With Atezolizumab Meets Primary Endpoint in Pancreatic Cancer	MT
Mar. 26	Novocure Announces Positive Topline Results From Phase 2 PANOVA-4 Clinical Trial Of Tumor Treating Fields Therapy For Metastatic Pancreatic Cancer	CI
Mar. 02	Novocure Announces Optune Lua®? Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer	CI
Mar. 02	Novocure Says It Receives Japan Reimbursement Approval For Optune Lua	MT
Feb. 26	NovoCure Limited, Q4 2025 Earnings Call, Feb 26, 2026
Feb. 26	NovoCure's Q4 Net Loss Narrows, Revenue Rises; 2026 Revenue Guidance Issued	MT
Feb. 26	NovoCure Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Feb. 26	Earnings Flash (NVCR) Novocure Reports Q4 Loss $0.22 a Share, vs. FactSet Est of $0.41 Loss	MT
Feb. 26	Earnings Flash (NVCR) Novocure Reports Q4 Revenue $174.4M, vs. FactSet Est of $173.3M	MT
Feb. 26	NovoCure Limited Provides Earnings Guidance for the Full Year 2026	CI
Feb. 24	Novocure Ltd says CMS reinstates Medicare billing privileges retroactively - SEC filing	RE
Feb. 12	FDA approves first-of-its-kind device to treat pancreatic cancer	RE